References
- The National Institute of Mental Health. Schizophrenia. Available from http://www.nimh.nih.gov/health/statistics/prevalence/schizophrenia.shtml. Accessed May 6, 2015.
- Lehman AF, Lieberman JA, Dixon LB, et al. Practice Guideline for the Treatment of Patients with Schizophrenia. 2nd ed. American Psychiatric Association; 2010. Available from: http://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/schizophrenia.pdf. Accessed November 7, 2014.
- McEvoy JP, Lieberman JA, Stroup TS, et al; CATIE Investigators. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry. 2006;163(4):600–610.
- Souza JS, Kayo M, Tassell I, Martins CB, Elkis H. Efficacy of olanzapine in comparison with clozapine for treatment-resistant schizophrenia: evidence from a systematic review and meta-analyses. CNS Spectr. 2013;18(2):82–89.
- VERSACLOZ (clozapine) oral suspension [package insert]. Palo Alto, CA: Jazz Pharmaceuticals, Inc.; 2013.
- Kamerow D. The pros and cons of generic drugs. BMJ. 2011;343:d4584.
- US Food and Drug Administration. CFR – Code of Federal Regulations Title 21 [webpage on the Internet]. 21CFR820.30. Quality System Regulation. Design Controls. Silver Spring, MD: US Food and Drug Administration; 2014 [updated September 1, 2014]. Available from: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm?fr=820.30. Accessed October 29, 2014.
- US Food and Drug Administration. Draft Guidance for Industry and Food and Drug Administration Staff – Applying Human Factors and Usability Engineering to Optimize Medical Device Design [webpage on the Internet]. Silver Spring, MD: US Food and Drug Administration; 2011 [updated September 4, 2014]. Available from: http://www.fda.gov/medicaldevices/deviceregulationandguidance/guidancedocuments/ucm259748.htm. Accessed May 6, 2015.